Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy Academic Article uri icon

abstract

  • Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy.We retrospectively identified a cohort of 40 patients with metastatic melanoma who received single-agent anti-PD-1 therapy with pembrolizumab or nivolumab and were treated on progression with ipilimumab at a dose of 3 mg kg(-1) for a maximum of four doses.Ten percent of patients achieved an objective response to ipilimumab, and an additional 8% experienced prolonged (>6 months) stable disease. Thirty-five percent of patients developed grade 3-5 immune-related toxicity associated with ipilimumab therapy. The most common high-grade immune-related toxicity was diarrhoea. Three patients (7%) developed grade 3-5 pneumonitis leading to death in one patient.Ipilimumab therapy can induce responses in patients who fail the anti-PD-1 therapy with response rates comparable to previous reports. There appears to be an increased frequency of high-grade immune-related adverse events including pneumonitis that warrants close surveillance.

authors

  • Parakh, Sagun
  • Bowyer, S
  • Prithviraj, P
  • Lorigan, P
  • Larkin, J
  • McArthur, G
  • Atkinson, V
  • Millward, M
  • Khou, M
  • Diem, S
  • Ramanujam, S
  • Kong, B
  • Liniker, E
  • Guminski, A
  • Parente, P
  • Andrews, MC
  • Parakh, S
  • Cebon, J
  • Long, GV
  • Carlino, MS
  • Klein, O

publication date

  • 2016